Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 4.07B 3.52B 3.33B 3.02B 5.66B 390B 5.7B 39.73B 15.31B 198B 15.28B 14.94B 629B P/E 2026 *
9.27x
P/E 2027 * 8.4x
Enterprise Value 4.06B 3.51B 3.32B 3.01B 5.64B 389B 5.68B 39.61B 15.26B 197B 15.23B 14.9B 627B EV / Sales 2026 *
3.04x
EV / Sales 2027 * 2.5x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 week+5.27%
1 month+20.78%
3 months+60.36%
6 months+29.91%
Current year+20.90%
1 week 1,160
Extreme 1160
1,264
1 month 975.5
Extreme 975.5
1,264
3 years 554.83
Extreme 554.83
2,020
5 years 335
Extreme 335
2,020
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%+5.27%+49.52%-20.18% 4.07B
+2.02%-0.96%+50.69%+92.40% 1,015B
+0.28%-3.24%+49.57%+62.65% 642B
+1.81%+2.07%+19.89%+70.38% 463B
-1.12%+2.14%+37.48%+36.98% 353B
-0.40%+1.59%+16.30%+23.11% 265B
-0.63%+1.90%+6.03%+10.62% 254B
+1.10%-12.75%+38.03%+45.44% 206B
-0.51%-4.33%-21.33%-58.09% 191B
+1.87%-3.04%+27.81%+89.26% 182B
Average +0.37%-3.35%+27.40%+35.26% 396.69B
Weighted average by Cap. +0.43%-2.21%+33.72%+56.73%

Financials

2026 *2027 *
Net sales 1.33B 1.15B 1.09B 988M 1.85B 128B 1.87B 13.01B 5.01B 64.76B 5B 4.89B 206B 1.4B 1.21B 1.14B 1.04B 1.95B 134B 1.96B 13.67B 5.27B 68.05B 5.26B 5.14B 216B
Net income 474M 411M 388M 352M 660M 45.46B 665M 4.63B 1.78B 23.06B 1.78B 1.74B 73.31B 530M 459M 433M 393M 738M 50.8B 743M 5.18B 1.99B 25.77B 1.99B 1.95B 81.92B
Net Debt -12.5M -10.83M -10.22M -9.27M -17.4M -1.2B -17.52M -122M -47.04M -608M -46.95M -45.91M -1.93B -570M -494M -466M -423M -793M -54.63B -799M -5.57B -2.15B -27.71B -2.14B -2.09B -88.11B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
34.47USD
Average target price
49.00USD
Spread / Average Target
+42.15%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!